Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 569

1.

Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.

Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki AB, Mahmud SM, Wheeler CM, Rivera-Paredez B, Hernández-López R, León-Maldonado L, Salmerón J; FRIDA Study Group.

JAMA Netw Open. 2019 Nov 1;2(11):e1915781. doi: 10.1001/jamanetworkopen.2019.15781.

PMID:
31747033
2.

Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology.

Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, Stoler MH, Ronnett BM, Joste NE, Darragh TM, Gravitt PE, Schiffman M, Hunt WC, Kinney WK, Wheeler CM; New Mexico HPV Pap Registry Steering Committee; p16 IHC Study Panel.

Arch Pathol Lab Med. 2019 Nov 13. doi: 10.5858/arpa.2019-0241-OA. [Epub ahead of print]

PMID:
31718233
3.

The Parkinson's Disease Mendelian Randomization Research Portal.

Noyce AJ, Bandres-Ciga S, Kim J, Heilbron K, Kia D, Hemani G, Xue A, Lawlor DA, Smith GD, Duran R, Gan-Or Z, Blauwendraat C, Gibbs JR; 23andMe Research Team5, International Parkinson's Disease Genomics Consortium (IPDGC), Hinds DA, Yang J, Visscher P, Cuzick J, Morris H, Hardy J, Wood NW, Nalls MA, Singleton AB.

Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873. [Epub ahead of print]

PMID:
31659794
4.

Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: a TransATAC study.

Buus R, Sestak I, Barron S, Loughman T, Fender B, Ruiz CL, Dynoodt P, Wang CA, O'Leary D, Gallagher WM, Dowsett M, Cuzick J.

Clin Cancer Res. 2019 Oct 22. pii: clincanres.0712.2019. doi: 10.1158/1078-0432.CCR-19-0712. [Epub ahead of print]

PMID:
31641007
5.

Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.

Hernández-López R, Lorincz AT, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, Nedjai B, Mendiola-Pastrana I, León-Maldonado L, Rivera-Paredez B, Ramírez-Palacios P, Lazcano-Ponce E, Cuzick J, Salmerón J; FRIDA Study Group.

Clin Epigenetics. 2019 Oct 12;11(1):140. doi: 10.1186/s13148-019-0743-9.

6.

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.

JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

7.

Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia.

Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1816-1824. doi: 10.1158/1055-9965.EPI-19-0239. Epub 2019 Sep 5.

PMID:
31488417
8.

A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model.

Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA.

J Breast Imaging. 2019 Jun;1(2):99-106. doi: 10.1093/jbi/wbz006. Epub 2019 May 11.

9.

Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial.

Brenner A, Afolabi A, Ahmad SM, Arribas M, Chaudhri R, Coats T, Cuzick J, Gilmore I, Hawkey C, Jairath V, Javaid K, Kayani A, Mutti M, Nadeem MA, Shakur-Still H, Stanworth S, Veitch A, Roberts I; HALT-IT Trial Collaborators.

Trials. 2019 Jul 30;20(1):467. doi: 10.1186/s13063-019-3561-7.

10.

A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.

Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR.

Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32541. [Epub ahead of print]

PMID:
31251818
11.

Predicting late recurrence in ER-positive breast cancer.

Cuzick J.

Nat Rev Clin Oncol. 2019 Jul;16(7):406-408. doi: 10.1038/s41571-019-0228-y. No abstract available.

PMID:
31092902
12.

Screening performance of abbreviated versions of the UPSIT smell test.

Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ.

J Neurol. 2019 Aug;266(8):1897-1906. doi: 10.1007/s00415-019-09340-x. Epub 2019 May 3.

13.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

14.

The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death.

Berney DM, Beltran L, Sandu H, Soosay G, Møller H, Scardino P, Murphy J, Ahmad A, Cuzick J; Transatlantic Prostate Group.

Histopathology. 2019 Oct;75(4):589-597. doi: 10.1111/his.13888. Epub 2019 Aug 13.

15.

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R.

Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016. Epub 2019 Apr 24.

16.

Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.

Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G, Beltran L, Cuzick J, Berney DM.

Mod Pathol. 2019 Sep;32(9):1303-1309. doi: 10.1038/s41379-019-0268-y. Epub 2019 Apr 11.

PMID:
30976102
17.

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.

Evans DGR, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, Sampson S, Southworth J, Stavrinos P, Howell SJ, Maxwell AJ, Howell A, Newman WG, Cuzick J.

Breast Cancer Res Treat. 2019 Jul;176(1):141-148. doi: 10.1007/s10549-019-05210-2. Epub 2019 Apr 2.

18.

A response to "Personalised medicine and population health: breast and ovarian cancer".

Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E.

Hum Genet. 2019 Mar;138(3):287-289. doi: 10.1007/s00439-019-01984-z. Epub 2019 Feb 27. No abstract available.

19.

Prediction of reader estimates of mammographic density using convolutional neural networks.

Ionescu GV, Fergie M, Berks M, Harkness EF, Hulleman J, Brentnall AR, Cuzick J, Evans DG, Astley SM.

J Med Imaging (Bellingham). 2019 Jul;6(3):031405. doi: 10.1117/1.JMI.6.3.031405. Epub 2019 Jan 31.

PMID:
30746393
20.

The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing.

Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E, Hopper JL, Trainer AH, Mann GB, Bickerstaffe A, Antoniou AC, Cuzick J, Phillips KA.

JMIR Form Res. 2018 Nov 7;2(2):e24. doi: 10.2196/formative.9935.

21.

Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry.

Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM; Transatlantic Prostate Group.

Am J Surg Pathol. 2019 Mar;43(3):361-368. doi: 10.1097/PAS.0000000000001202.

PMID:
30531531
22.

Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply.

Brentnall AR, Buist DSM, Cuzick J.

JAMA Oncol. 2019 Jan 1;5(1):111. doi: 10.1001/jamaoncol.2018.5102. No abstract available.

PMID:
30452738
23.

Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention.

Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN.

Eur J Cancer Prev. 2019 Nov;28(6):500-506. doi: 10.1097/CEJ.0000000000000493.

PMID:
30444752
24.

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2019 May 15;144(10):2587-2595. doi: 10.1002/ijc.31976. Epub 2018 Dec 24.

25.

Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I.

Trials. 2018 Oct 1;19(1):533. doi: 10.1186/s13063-018-2900-4.

26.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

27.

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

28.

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.

Lo LL, Milne RL, Liao Y, Cuzick J, Terry MB, Phillips KA.

Br J Cancer. 2018 Jul;119(1):36-39. doi: 10.1038/s41416-018-0120-z. Epub 2018 Jun 21.

29.

Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2018 Jun 8;20(1):49. doi: 10.1186/s13058-018-0979-x.

30.

Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.

Ahmad AS, Parameshwaran V, Beltran L, Fisher G, North BV, Greenberg D, Soosay G, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group.

Oncotarget. 2018 Apr 17;9(29):20555-20562. doi: 10.18632/oncotarget.24994. eCollection 2018 Apr 17.

31.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

32.

Prognosis vs Treatment Interaction.

Cuzick J.

JNCI Cancer Spectr. 2018 Apr 28;2(1):pky006. doi: 10.1093/jncics/pky006. eCollection 2018 Jan.

33.

Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.

Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG.

Breast Cancer Res Treat. 2018 Aug;170(3):633-640. doi: 10.1007/s10549-018-4775-1. Epub 2018 Apr 24.

34.

Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.

Cuzick J.

Br J Cancer. 2018 May;118(9):1155-1161. doi: 10.1038/s41416-018-0039-4. Epub 2018 Apr 23. Review.

35.

Molecular progression to cervical precancer, epigenetic switch or sequential model?

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Oct 1;143(7):1720-1730. doi: 10.1002/ijc.31549. Epub 2018 Jul 3.

36.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

37.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
38.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.

Brentnall AR, Cuzick J, Buist DSM, Bowles EJA.

JAMA Oncol. 2018 Sep 1;4(9):e180174. doi: 10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13.

39.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

40.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524.

41.

A comparison of five methods of measuring mammographic density: a case-control study.

Astley SM, Harkness EF, Sergeant JC, Warwick J, Stavrinos P, Warren R, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Brentnall AR, Cuzick J, Howell T, Evans DG.

Breast Cancer Res. 2018 Feb 5;20(1):10. doi: 10.1186/s13058-018-0932-z.

42.

Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK.

Evans DG, Brentnall AR, Harvie M, Astley S, Harkness EF, Stavrinos P, Donnelly LS, Sampson S, Idries F, Watterson D, Cuzick J, Wilson M, Jain A, Harrison F, Maxwell AJ, Howell A.

BMC Public Health. 2018 Jan 25;18(1):178. doi: 10.1186/s12889-018-5090-9.

43.

The Value of Helicobacter Eradication in Long-term Aspirin Users.

Cuzick J.

J Natl Cancer Inst. 2018 Jul 1;110(7):690-691. doi: 10.1093/jnci/djx289. No abstract available.

44.

Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction.

van Veen EM, Brentnall AR, Byers H, Harkness EF, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR.

JAMA Oncol. 2018 Apr 1;4(4):476-482. doi: 10.1001/jamaoncol.2017.4881.

45.

SNPs for breast cancer risk assessment.

Cuzick J, Brentnall A, Dowsett M.

Oncotarget. 2017 Nov 3;8(59):99211-99212. doi: 10.18632/oncotarget.22278. eCollection 2017 Nov 21. No abstract available.

46.

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J.

Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.

47.

RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.

Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2.

48.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

49.

Need for expanded HPV genotyping for cervical screening.

Cuzick J, Wheeler C.

Papillomavirus Res. 2016 Dec;2:112-115. doi: 10.1016/j.pvr.2016.05.004. Epub 2016 Jun 1.

50.

A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2017 Oct 18;19(1):114. doi: 10.1186/s13058-017-0906-6.

Supplemental Content

Loading ...
Support Center